Background
Methods
Patients
Statistical analysis
Results
Patient characteristics
Characteristic | RSCC | LSCRC |
P value |
---|---|---|---|
Sex | 0.107 | ||
Male | 30 (60%) | 104 (72.2) | |
Female | 20 (40%) | 40 (28.8) | |
Age | 55.50 (23–75) | 60 (20–75) | 0.311 |
Liver metastasis | 0.293 | ||
Single lesion | 8 (16%) | 15 (10.4) | |
Multiple lesions | 42 (84%) | 129 (89.6) | |
Diameter of liver metastasis | 0.644 | ||
<3 cm | 20 (40%) | 63 (43.8%) | |
≥3 cm | 30 (60%) | 81 (56.2%) | |
CEA (ng/ml) | 0.646 | ||
<200 | 40 (80%) | 105 (72.9%) | |
≥200 | 10 (20%) | 39 (27.1%) | |
CA199 (U/ml) | 0.644 | ||
<35 | 20 (40%) | 63 (43.8%) | |
≥35 | 30 (60%) | 81 (56.2%) | |
Systemic chemotherapy | 0.194 | ||
No | 10 (20) | 18 (5.6%) | |
Yes | 40 (80) | 126 (94.4%) | |
Target agent | 0.970 | ||
None | 39 (78%) | 109 (75.7%) | |
C225 | 5 (10%) | 12 (8.3%) | |
Avastin | 4 (8%) | 15 (10.4%) | |
Both | 1 (2%) | 4 (2.8%) | |
Other | 1 (2%) | 4 (2.8%) |
Characteristics | RSCC | LSCRC |
P value |
---|---|---|---|
Sex | 0.179 | ||
Male | 20 (58.8) | 65 (71.4) | |
Female | 14 (41.2) | 26 (28.6) | |
Age | 55.50 (23–75) | 60 (20–75) | 0.129 |
T stage | 0.060 | ||
T1 | 0 (0) | 1 (1.1) | |
T2 | 3 (8.9) | 7 (7.7) | |
T3 | 6 (17.6) | 29 (31.9) | |
T4a | 23 (67.6) | 54 (59.3) | |
T4b | 2 (5.9) | 0 (0) | |
N stage | 0.977 | ||
N0 | 12 (35.3) | 33 (36.3) | |
N1 | 10 (29.4) | 25 (27.5) | |
N2 | 12 (35.3) | 33 (36.3) | |
LVI | 0.641 | ||
None | 28 (82.4) | 78 (85.7) | |
Yes | 6 (17.6) | 13 (14.3) | |
PNI | 0.719 | ||
None | 30 (88.2) | 84 (92.3) | |
Yes | 4 (11.8) | 7 (7.7) | |
Histological types | 0.270 | ||
Highly differentiated ADC | 0 (0) | 0 (0) | |
Middle differentiated ADC | 21 (61.8) | 65 (71.4) | |
Poorly differentiated ADC | 12 (35.3) | 20 (22) | |
Undifferentiated ADC | 1 (2.9) | 6 (6.6) | |
Regional LNs | 13.15 (0–41) | 9.74 (0–32) | 0.012 |
Metastatic LNs | 3.64 (0–21) | 2.98 (0–19) | 0.447 |
Liver metastasis | 0.489 | ||
Single lesion | 7 (20.6) | 14 (15.4) | |
Multiple lesions | 27 (79.4) | 77 (84.6) | |
Diameter of liver metastasis | 0.275 | ||
<3 cm | 12 (35.3) | 42 (46.2) | |
≥3 cm | 22 (64.7) | 49 (53.8) | |
CEA | 0.646 | ||
<200 | 26 (76.5) | 73 (80.2) | |
≥200 | 8 (23.5) | 18 (19.8) | |
CA199 | 0.275 | ||
<35 | 14 (41.2) | 44 (48.4) | |
≥35 | 20 (58.8) | 47 (51.6) | |
Systemic chemotherapy | 0.250 | ||
No | 10 (29) | 18 (19.8) | |
Yes | 24 (71) | 73 (80.2) | |
Target agent | 0.836 | ||
None | 28 (82.4) | 72 (79.1) | |
C225 | 3 (8.8) | 5 (5.5) | |
Avastin | 2 (5.9) | 6 (6.6) | |
Both | 1 (2.9) | 4 (4.4) | |
Other | 0 (0.0) | 4 (4.4) |
Treatment
Survival time
Overall survival | ||||
---|---|---|---|---|
Univariate | Multivariate | |||
Variables | RR (95% CI) |
P value | RR (95% CI) |
P value |
Primary location | 0.603 (0.407–0.893) |
0.012
| 0.569 (0.377–0.858) |
0.007
|
T stage | 1.384 (0.190–10.062) | 0.748 | ||
LVI | 1.182 (0.819–1.708) | 0.372 | ||
PNI | 1.456 (0.722–2.937) | 0.293 | ||
N stage | 1.123 (0.267–4.717) | 1.123 | ||
Regional LNs | 0.981 (0.948–1.016) | 0.281 | ||
Metastasis LNs | 1.055 (1.006–1.106) | 0.207 | ||
Sex | 1.260 (0.873–1.817) | 0.217 | ||
Diameter of LM | 1.766 (1.233–2.530) |
0.002
| 2.622 (1.618–4.248) |
0.001
|
Neo-chemo | 1.122 (0.654–1.925) | 0.676 | ||
Histological type | 1.733 (1.273–2.357) |
0.001
| 0.194 (0.075–0.501) |
0.001
|
CA199 | 1.727 (1.209–2.466) |
0.003
| ||
Number of LM | 2.330 (1.279–4.246) |
0.006
| 2.134 (1.420–3.205) |
0.001
|
CEA | 1.926 (1.309–2.834) |
0.001
| 1.624 (1.054–2.503) |
0.028
|
Systemic chemo | 0.738 (0.458–1.190) | 0.213 | 0.582 (0.350–0.968) |
0.037
|
Palliative resection | 1.542 (1.065–2.232) |
0.022
| 1.034 (0.973–1.098) | 0.285 |
Overall survival | ||||||||
---|---|---|---|---|---|---|---|---|
RSCCs | LSCRs | |||||||
Univariate | Multivariate | Univariate | Multivariate | |||||
Variable | RR (95% CI) |
P
| RR (95% CI) |
P
| RR (95% CI) |
P
| RR (95% CI) |
P
|
T stage | 2.284 (0.205–25.41) | 0.502 | 0.271 (0.064–1.141) | 0.075 | ||||
LVI | 1.219 (0.449–3.306) | 0.697 | 1.198 (0.794–1.807) | 0.389 | ||||
PNI | 0.595 (0.211–2.441) | 0.717 | 1.913 (0.806–.542) | 0.142 | ||||
N stage | 0.911 (0.267–4.717) | 0.847 | 0.566 (0.131–2.445) | 0.446 | ||||
Regional LNs | 0.973 (0.913–1.036) | 0.388 | 0.90 (.929–.013) | 0.170 | ||||
Metastasis LNs | 1.040 (0.960–1.126) | 0.336 | 1.04 (0.987–1.112) | 0.123 | ||||
Sex | 1.363 (0.693–2.681) | 0.369 | 1.143 (0.735–1.778) | 0.553 | ||||
Diameter of LM | 1.705 (0.833–3.491) | 0.144 | 1.75 (.153–2.656) |
0.009
| ||||
Neo-chemo | 2.263 (0.931–5.504) | 0.072 | 0.846 (0.424–1.686) | 0.635 | ||||
Histological type | 2.696 (1.327–5.476) |
0.006
| 0.313 (0.134–0.729) |
0.02
| 0.519 (0.203–0.923) |
0.001
| 0.346 (0.131–0.913) |
0.032
|
CA199 | 0.826 (0.426–1.621) | 0.578 | 2.087 (1.371–3.177) |
0.001
| ||||
Number of LM | 1.864 (0.886–3.923) | 0.101 | 2.022 (1.274–3.211) |
0.003
| 2.183 (1.243–3.833) |
0.007
| ||
CEA | 1.075 (0.503–2.300) | 0.852 | 2.310 (1.42–624) |
0.001
| ||||
Systemic chemo | 0.620 (0.267–1.442) | 0.267 | 0.830 (0.462–1.492) | 0.533 | ||||
Palliative resection | 1.041 (0.500–2.179) | 0.910 | 1.767 (11.15–2.716) |
0.009
| 1.767 (1.150–2.716) |
0.011
|